Fall 2024

Healey & AMG Center for ALS is paving the way in Expanding Access to Investigational Drugs

At the Sean M. Healey & AMG Center for ALS, we are committed to providing people with ALS who are not eligible for clinical trials access to experimental therapies. Across the country, Expanded Access Protocol (EAP) programs are creating new avenues of hope for those living with the disease, and providing valuable research information that brings us closer to a cure. The introduction and expansion of these programs represent a significant step forward in our collective fight against ALS.

Together, as a community, we continue to push the boundaries of what is possible in ALS research and treatment.

See the map of participating sites here.

For more information about EAPs, including how to explore potential options, visit our website and join our Expanded Access Webinars.

EAP Progress to Date

Expanded Access Webinars

The Healey & AMG Center hosts public Q&A webinars for the ALS community. Join us on select Thursdays at 5:00-5:30 pm EST to discuss news and updates about Expanded Access, ask questions, and hear from doctors and industry professionals at MGH and beyond.

This month, Suma Babu, MBBS, MPH of Massachusetts General Hospital was joined by guest speakers Dr. David Walk from the University of Minnesota and David Kolquist of Never Surrender Inc to discuss collaborative efforts to build more Expanded Access opportunities for people impacted by ALS. 

Upcoming Webinars

• Thursday, December 12th, 5:00 pm EST: Monthly EAP Discussion

To register for future webinars and view past recordings, visit our website

Actively Enrolling Opportunities

Pridopidine EAP2

Pridopidine is a highly selective Sigma-1 receptor agonist developed by Prilenia for the treatment of neurodegenerative and neurodevelopmental disorders. We are currently enrolling participants for this EAP, with several sites activated.

View the Pridopidine EAP on ClinicalTrials.gov

Watch a webinar about the science behind Pridopidine 

RAPA-501 EAP

RAPA-501 is an epigenetically reprogrammed autologous cell therapy aimed at reducing inflammation and slowing the progression of ALS. RAPA-501 cells are manufactured ex-vivo to attain dual TREG/Th2 anti-inflammatory activity and a T-stem phenotype that permits T cell therapy without conditioning chemotherapy.

View the RAPA-501 EAP on ClinicalTrials.gov

Watch a webinar about the science behind RAPA-501

Latest Publications

Multicenter Expanded Access Program for Access to Investigational Products for Amyotrophic Lateral Sclerosis

Neel D, Baselga-Garriga C, Benson M, Keegan M, Chase M, D'Agostino D, Drake K, Hagar J, Hasenoehrl M, Kulesa-Kelley J, Leite A, Mohapatra S, Portaro S, Pothier L, Rosenthal J, Sherman A, Yu H, McCaffrey A, Ho D, Luppino S, Bedlack R, Heitzman D, Ajroud-Driss S, Katz J, Felice K, Whitaker C, Ladha S, Alameda G, Locatelli E, Qureshi I, Hotchkin M, Hayden M, Cudkowicz M, Babu S, Berry J, Paganoni S. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis. Muscle & Nerve. 2024 June 6. doi: 10.1002/mus.28169.

Read the full article

View the full list of publications from the Healey & AMG Center for ALS here